Denali Therapeutics Inc. Common Stock (DNLI) is a publicly traded Healthcare sector company. As of October 8, 2026, DNLI trades at $19.08 with a market cap of $3.08B and a P/E ratio of -6.99. DNLI moved -0.42% today. Year to date, DNLI is +17.76%; over the trailing twelve months it is +28.59%. Its 52-week range spans $10.57 to $27.30. Analyst consensus is strong buy with an average price target of $35.92. Rallies surfaces DNLI's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks DNLI insider trades, Form 4 activity, executive purchases, executive sales, shares, prices, and transaction dates when available.
| Metric | Value |
|---|---|
| Price | $19.08 |
| Market Cap | $3.08B |
| P/E Ratio | -6.99 |
| EPS | $-2.84 |
| Dividend Yield | 0.00% |
| 52-Week High | $27.30 |
| 52-Week Low | $10.57 |
| Volume | 6.92K |
| Avg Volume | 0 |
| Revenue (TTM) | $3.60M |
| Net Income | $-511.45M |
| Gross Margin | 0.00% |
15 analysts cover DNLI: 0 strong buy, 15 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $35.92.